A Phase I, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMP-224 in a Regimen Containing Cyclophosphamide in Patients with Advanced Solid Malignancies (Amplimmune AMP-224-01).

Trial Profile

A Phase I, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMP-224 in a Regimen Containing Cyclophosphamide in Patients with Advanced Solid Malignancies (Amplimmune AMP-224-01).

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs AMP 224 (Primary) ; Cyclophosphamide
  • Indications Malignant melanoma; Ovarian cancer; Solid tumours; T cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Amplimmune
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Apr 2013 Data will be presented at the American Association for Cancer Research Annual Meeting 2013, according to a Sarah Cannon Research Institute media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top